HomeInsightsStock Comparison

Accretion Pharmaceuticals Ltd vs Concord Biotech Ltd Stock Comparison

Accretion Pharmaceuticals Ltd vs Concord Biotech Ltd Stock Comparison

Last Updated on: Jul 16, 2025

Key Highlights

  • The Latest Trading Price of Accretion Pharmaceuticals Ltd is ₹ 64.75 as of 16 Jul 14:59.
  • The P/E Ratio of Accretion Pharmaceuticals Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Concord Biotech Ltd changed from 51.7 on March 2024 to 51.7 on March 2024 . This represents a CAGR of 0.00% over 1 years.
  • The Market Cap of Accretion Pharmaceuticals Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Concord Biotech Ltd changed from ₹ 15922 crore on March 2024 to ₹ 15922 crore on March 2024 . This represents a CAGR of 0.00% over 1 years.
  • The revenue of Accretion Pharmaceuticals Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Concord Biotech Ltd for the Mar '25 is ₹ 439.27 crore as compare to the Dec '24 revenue of ₹ 260.78 crore. This represent the growth of 68.44%.
  • The ebitda of Accretion Pharmaceuticals Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Concord Biotech Ltd for the Mar '25 is ₹ 198.26 crore as compare to the Dec '24 ebitda of ₹ 114.51 crore. This represent the growth of 73.14%.
  • The net profit of Accretion Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Concord Biotech Ltd changed from ₹ 54.49 crore to ₹ 140.39 crore over 8 quarters. This represents a CAGR of 60.51% .
  • The Dividend Payout of Accretion Pharmaceuticals Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Concord Biotech Ltd changed from 24.05 % on March 2020 to 30.03 % on March 2024 . This represents a CAGR of 4.54% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Accretion Pharmaceuticals Ltd

  • Accretion Pharmaceuticals was incorporated in year 2012, the Promoters Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel, Mr. Mayur Popatlal Sojitra and Mr. Hardik Mukundbhai Prajapati, came together to establish a pharmaceutical manufacturing unit, to provide health care products.
  • Thus, the foundation of 'Accretion Pharmaceuticals' was laid down, which was started as a Partnership Firm in the name of 'M/s Accretion Pharmaceuticals', pursuant to a deed of partnership dated December 18, 2012. The manufacturing facility which is currently located at Ahmedabad, in Sanand District of Gujarat, commenced its manufacturing operations in year 2014.
  • Thereafter, the Partnership Firm was converted into a Limited Company in the name of 'Accretion Pharmaceuticals Limited' and a certificate of incorporation dated November 29, 2023 was issued by the Registrar of Companies, Central Registration Centre, for and on behalf of the jurisdictional Registrar of Companies.

About Concord Biotech Ltd

  • Concord Biotech Limited was originally incorporated as Servomed Pharmaceuticals Private Limited' at Ahmedabad, Gujarat as a Private Limited Company dated November 23, 1984, issued by the Registrar of Companies.
  • Thereafter, name of the Company was changed to Concord Biotech Limited' dated February 16, 2001, which became a Public Company and a fresh Certificate of Incorporation dated November 7, 2001 was issued by the RoC. The Company is an India-based bio pharma and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India.
  • Presently, it is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products.

Accretion Pharmaceuticals Ltd News Hub

News

Accretion Pharmaceuticals to discuss results

Accretion Pharmaceuticals will hold a meeting of the Board of Directors of the Company on ...

Read more

05 Jun 2025 10:16

News

NSE SME Accretion Pharma stumbles on market debut

The scrip was listed at 79, a discount of 21.78% over the initial public offer (IPO) price...

Read more

21 May 2025 10:38

News

NSE SME Accretion Pharmaceuticals' IPO ends with subscription of 7.31 times

The initial public offer (IPO) of Accretion Pharmaceuticals received bids for 2,00,06,400 ...

Read more

19 May 2025 11:43

Concord Biotech Ltd News Hub

News

Concord Biotech acquires 75% stake in Stellon Biotech

Concord Biotech has made an equity investment of USD 1,500 in Stellon Biotech Inc. This in...

Read more

02 Jul 2025 12:10

News

Concord Biotech edges higher on value buying; trades above 100-day SMA

The scrip had declined 15.63% in seven sessions to end at Rs 1,780.75 yesterday, from its ...

Read more

25 Jun 2025 11:40

News

Concord Biotech's API facility completes USFDA inspection

Concord Biotech has received an Establishment Inspection Report (EIR) from the US Food and...

Read more

24 Jun 2025 19:06

News

Board of Concord Biotech recommends final dividend

Concord Biotech announced that the Board of Directors of the Company at its meeting held o...

Read more

30 May 2025 11:14

News

Concord Biotech to announce Quarterly Result

Concord Biotech will hold a meeting of the Board of Directors of the Company on 29 May 202...

Read more

24 May 2025 18:40

News

Concord Biotech gets US FDA nod for marketing multiple sclerosis drug Teriflunomide

Teriflunomide tablets are used for the treatment of patients with relapsing forms of multi...

Read more

09 Apr 2025 09:18

SWOT Analysis Of Concord Biotech Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Concord Biotech Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Accretion Pharmaceuticals Ltd and Concord Biotech Ltd

Which company has a larger market capitalization, Accretion Pharmaceuticals Ltd or Concord Biotech Ltd?

Market cap of Accretion Pharmaceuticals Ltd is 72 Cr while Market cap of Concord Biotech Ltd is 19,226 Cr

What are the key factors driving the stock performance of Accretion Pharmaceuticals Ltd and Concord Biotech Ltd?

The stock performance of Accretion Pharmaceuticals Ltd and Concord Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Accretion Pharmaceuticals Ltd and Concord Biotech Ltd?

As of July 16, 2025, the Accretion Pharmaceuticals Ltd stock price is INR ₹65.0. On the other hand, Concord Biotech Ltd stock price is INR ₹1837.8.

How do dividend payouts of Accretion Pharmaceuticals Ltd and Concord Biotech Ltd compare?

To compare the dividend payouts of Accretion Pharmaceuticals Ltd and Concord Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions